Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers

Affiliations

• ¹ Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ² Institute of Stroke and Cerebrovascular Disease, University of Texas Health Science Center at Houston, Houston, TX, USA.
• ³ Institutional Analytics & Informatics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁴ Cardtronics, Inc, Houston, TX, USA.
• ⁵ Core for Biomolecular Structure and Function, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁶ Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁷ Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁸ Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁹ Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
• ¹⁰ Director of Drug Discovery and Development, Advanced Organic Synthesis LLC, Houston, Texas, USA.
• ¹¹ Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹² Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹³ Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA. aettius@aol.com.